XERIS Pharmaceuticals Inc (XERS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:XERIS Pharmaceuticals Inc (XERS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7871
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. Its products are used for various therapeutic areas, including severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar control. The company caters caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

XERIS Pharmaceuticals Inc (XERS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Venture Financing 10
XERIS Pharma Raises USD10 Million in Series C Equity Financing 10
Xeris Pharma Raises Additional USD30 Million in Series C Financing 11
XERIS Pharma Raises USD0.2 Million in Venture Financing 13
Partnerships 14
Xeris Pharma Enters into Joint Development Agreement Scandinavian Health 14
Equity Offering 15
Xeris Pharma Raises USD98.3 Million in IPO of Shares 15
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 16
XERIS Pharmaceuticals Inc – Key Competitors 17
XERIS Pharmaceuticals Inc – Key Employees 18
XERIS Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 13, 2018: Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights 20
Corporate Communications 21
Sep 07, 2017: Xeris Pharmaceuticals Appoints John P. Schmid to Board of Directors 21
Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 22
Product News 23
Jun 05, 2017: Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
XERIS Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
XERIS Pharma Raises USD10 Million in Series C Equity Financing 10
Xeris Pharma Raises Additional USD30 Million in Series C Financing 11
XERIS Pharma Raises USD0.2 Million in Venture Financing 13
Xeris Pharma Enters into Joint Development Agreement Scandinavian Health 14
Xeris Pharma Raises USD98.3 Million in IPO of Shares 15
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 16
XERIS Pharmaceuticals Inc, Key Competitors 17
XERIS Pharmaceuticals Inc, Key Employees 18

List of Figures
XERIS Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[XERIS Pharmaceuticals Inc (XERS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Smiths Medical:企業の戦略的SWOT分析
    Smiths Medical - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Micropole SA (MUN):企業の財務・戦略的SWOT分析
    Micropole SA (MUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Ono Pharmaceutical Co Ltd (4528)-医療機器分野:企業M&A・提携分析
    Summary Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a research-based pharmaceutical company, which carries out the discovery, production and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of diseases such as type I …
  • Jardine Matheson Holdings Limited:戦略・SWOT・企業財務分析
    Jardine Matheson Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Matheson Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Pratt Industries Inc:戦略・SWOT・企業財務分析
    Pratt Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Pratt Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Med BioGene Inc (MBI)-医療機器分野:企業M&A・提携分析
    Summary Med BioGene Inc (Med BioGene) is a life sciences company, which develops and commercializes genome-based clinical laboratory diagnostic tests. The company’s lead test under development, GeneFx Lung formerly LungExpress Dx, is a proprietary gene expression based test. Its GeneFx Lung test is …
  • Emerson Electric Co (EMR):企業の財務・戦略的SWOT分析
    Emerson Electric Co (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Eisai Co Ltd (4523):製薬・医療:M&Aディール及び事業提携情報
    Summary Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eis …
  • Bayer AG (BAYN):医療機器:M&Aディール及び事業提携情報
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. The company's pr …
  • NicOx SA (COX):企業の財務・戦略的SWOT分析
    Summary Nicox SA is an ophthalmology company developing solutions to help maintain vision and improve ocular health. The company is engaged in the research, development and marketing investigational drugs for ophthalmological diseases. The aims to produce therapeutic products which aims to address t …
  • Amoy Diagnostics Co Ltd (300685):医療機器:M&Aディール及び事業提携情報
    Summary Amoy Diagnostics Co Ltd (AmoyDx) is a developer of molecular diagnostics for oncology precision medicine. The company provides gene mutation products such as mutation detection kit and gene fusions detection kit. It offers nucleic acid extraction products including DNA and RNA extraction kit …
  • UNITIKA LTD.:企業の戦略・SWOT・財務情報
    UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report Summary UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sanofi Genzyme:企業のM&A・事業提携・投資動向
    Sanofi Genzyme - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sanofi Genzyme Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Echelon Corporation (ELON):企業の財務・戦略的SWOT分析
    Echelon Corporation (ELON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Akers Biosciences Inc (AKER):企業の財務・戦略的SWOT分析
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. ABI products include BreathScan alcohol detectors, CHUBE, METRO …
  • PTT Public Company Limited:企業の戦略・SWOT・財務情報
    PTT Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary PTT Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Noble Corporation plc:企業の戦略・SWOT・財務分析
    Noble Corporation plc - Strategy, SWOT and Corporate Finance Report Summary Noble Corporation plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • GenomicTree Inc:企業の製品パイプライン分析2018
    Summary GenomicTree Inc (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung and …
  • MMC Corp Bhd (MMCCORP):企業の財務・戦略的SWOT分析
    Summary MMC Corp Bhd (MMC) is an investment holding company which carries out mining, mineral exploration and construction services. It operates through ports and logistics, energy and utilities, engineering and industrial development divisions. The company offers containers, bulk and breakbulk, liq …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆